Back to Search
Start Over
Successful Treatment with Letermovir in a Heart Transplant Recipient with UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Colitis and Viremia.
- Source :
-
International heart journal [Int Heart J] 2023 Mar 31; Vol. 64 (1), pp. 95-99. Date of Electronic Publication: 2023 Jan 23. - Publication Year :
- 2023
-
Abstract
- Currently available anti-cytomegalovirus (CMV) agents are sometimes poorly tolerated, owing to their side effects. Letermovir is a novel anti-CMV drug that is only approved for CMV prophylaxis in hematopoietic stem cell transplant recipients, with fewer side effects. We report the case of a heart transplant recipient with UL97 mutation (L595F) ganciclovir-resistant cytomegalovirus colitis who was successfully treated with off-label use of letermovir. In treating CMV infection or disease with letermovir, a transient rise or lag in the clearance of CMV-DNA polymerase chain reaction levels has been observed. Our case suggests that CMV-pp65 antigenemia can be an additional marker of treatment efficacy.
- Subjects :
- Humans
Ganciclovir therapeutic use
Ganciclovir pharmacology
Antiviral Agents therapeutic use
Antiviral Agents pharmacology
Viremia drug therapy
Viremia etiology
Cytomegalovirus genetics
Mutation
Cytomegalovirus Infections drug therapy
Cytomegalovirus Infections prevention & control
Heart Transplantation adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1349-3299
- Volume :
- 64
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- International heart journal
- Publication Type :
- Academic Journal
- Accession number :
- 36682771
- Full Text :
- https://doi.org/10.1536/ihj.22-496